Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the method, and methods for using the cells
View Patent ↗The invention is directed to methods for culturing cells so that the cells are induced to differentiate into cells that express a hepatic stellate phenotype and cells that express a hepatic sinusoidal endothelial phenotype. The invention is also directed to cells produced by the methods of the invention. The cells are useful, among other things, for treatment of liver deficiency, liver metabolism studies, and liver toxicity studies.
1. A method for producing cells with a hepatic stellate phenotype and cells with a hepatic sinusoidal endothelial phenotype, comprising:
(a) culturing pluripotent cells with about 5 ng/ml to about 500 ng/ml Wnt3a and about 10 ng/ml to about 1,000 ng/ml ActivinA;
(b) then culturing the cells of step (a) with about 1 ng/ml to about 100 ng/ml bFGF and about 5 ng/ml to about 500 ng/ml BMP4;
(c) then culturing the cells of step (b) with about 5 ng/ml to about 500 ng/ml aFGF, about 1 ng/ml to about 100 ng/ml FGF4 and about 2.5 ng/ml to about 250 ng/ml FGF8b;
(d) then culturing the cells of step (c) with about 2 ng/ml to about 200 ng/ml HGF and about 10 ng/ml to about 1,000 ng/ml Follistatin; and
(e) isolating hepatic stellate cells and/or hepatic endothelial sinusoidal cells produced by the differentiation protocol, wherein the pluripotent cells are non-embryonic germ cells, embryonic stem cells, or germ cells and can differentiate into at least one cell type of at least two of the endodermal, ectodermal, and mesodermal embryonic lineages and/or express oct4 or telomerase.
2. The method of claim 1 , wherein the pluripotent cells express telomerase.
3. The method of claim 1 , wherein the pluripotent cells express oct4.
4. The method of claim 1 , wherein the pluripotent cells can differentiate into at least one cell type of at least two of the endodermal, ectodermal, and mesodermal embryonic lineages.
5. The method of claim 1 , wherein the pluripotent cells express telomerase and can differentiate into at least one cell type of at least two of the endodermal, ectodermal, and mesodermal embryonic lineages.
6. The method of claim 1 , wherein the pluripotent cells express oct4 and can differentiate into at least one cell type of at least two of the endodermal, ectodermal, and mesodermal embryonic lineages.
7. The method of any of claims 1 and 2 - 6 , wherein the cells that are contacted with Wnt3a and ActivinA are human bone marrow-derived cells.
8. The method of claim 1 where isolation of hepatic stellate cells in step (e) is carried out by one or more markers selected from the group consisting of Vitamin A + , PPARg + , GFAP + , GPR91 + , ALCAM, CRBP high , p75NTR + , COL1a1 high , and TIMP-1 low .
9. The method of claim 1 where isolation of liver sinusoidal endothelial cells in step (e) is carried out using one or more markers selected from the group consisting of CD32b + , Stab-1 + , Stab-2 + , L-SIGN + , and MRC1 + .
10. A method for producing cells with a hepatic stellate phenotype and cells with a hepatic sinusoidal endothelial phenotype, comprising:
(a) culturing pluripotent cells with about 50 ng/ml Wnt3a and about 100 ng/ml ActivinA;
(b) then culturing the cells of step (a) with about 10 ng/ml bFGF and about 50 ng/ml BMP4;
(c) then culturing the cells of step (b) with about 50 ng/ml aFGF, about 10 ng/ml FGF4 and about 25 ng/ml FGF8b;
(d) then culturing the cells of step (c) with about 20 ng/ml HGF and about 100 ng/ml Follistatin; and
(e) isolating hepatic stellate cells and/or hepatic endothelial sinusoidal cells produced by the differentiation protocol, wherein the pluripotent cells express telomerase, oct4, and can differentiate into at least one cell type of at least two of the endodermal, ectodermal, and mesodermal embryonic lineages and are derived from human bone marrow.